Epstein-Barr Virus (EBV) is a ubiquitous human gammaherpesivrus that has been classified by the WHO as a class I carcinogen due to its consistent association with lymphoid and epithelial cell malignancies. EBV-associated tumors harbor latent viral genomes that persist as multicopy, chromatin-associated episomes. EBNA1 is the one viral protein known to be essential for episome maintenance and is the only viral protein consistently expressed in all EBV-associated tumors. EBNA1 is a multifunctional, sequence-specific DNA-binding protein that regulates viral DNA replication, episome maintenance, metaphase chromosome tethering, and transcription. EBNA1 is also required for host-cell survival. The molecular mechanisms for each of these functions are only partly understood, and more complete understanding is necessary for development of effective strategies to treat EBV latent infection and carcinogenesis. During the previous funding cycle, we showed that EBNA1 functions at the viral origin of plasmid DNA replication (OriP) through interactions with several host proteins important for chromosome integrity, including telomere repeat binding factors (TRFs), DNA replication pausing factors (Timeless and Tipin), and DNA recombination proteins (MRE11-RAD50-NBS1 or MRN). We have also shown that EBNA1 interacts with the origin recognition complex (ORC) in an RNA-dependent manner and that this correlates with metaphase chromosome attachment. To understand EBNA1 interactions with the host-chromosome, we used chromatin immunoprecipitation combined with next generation DNA sequencing (ChIP-Seq) and functional genomic methods to identify and characterize EBNA1 binding sites in the human genome. We now propose to advance these studies to better understand the role of EBNA1 in viral genome maintenance and host-cell survival during latent infection. We propose to test the overarching hypothesis that EBNA1 coordinates multiple aspects of viral genome persistence with host-cell fitness. We will test the specific hypotheses that EBNA1 (1) promotes recombination-dependent replication at OriP, (2) coordinates viral DNA replication and episome maintenance with telomere length regulation, and (3) modulates cellular gene expression and chromosome structures necessary for host-cell and viral episome survival during latent infection. Since EBNA1 is a prototypical genome maintenance protein, our studies will provide novel insight into the genome maintenance mechanisms shared by Kaposi's Sarcoma-Associated Herpesvirus (KSHV) LANA and human papillomavirus (HPV) E2 family members, as well as by cellular factors that protect fragile genetic elements, including telomeres and other repetitive DNA. More detailed understanding of EBNA1 is further justified by its potential value as a target for therapeutic intervention in diseases and cancers associated with EBV latent infection.

Public Health Relevance

Epstein-Barr virus (EBV) is estimated to be responsible for ~1% of all human cancer world-wide, including most forms of post-transplant lymphoproliferative disease, ~50% of Hodgkin's disease, ~10% of gastric carcinomas, and the majority of endemic forms of Burkitt's lymphoma and nasopharyngeal carcinomas. The overwhelming majority of EBV-associated tumors harbor latent viral genomes that are maintained through the action of the viral encoded protein EBNA1. This grant focuses on the mechanisms of EBNA1-mediated genome maintenance and how this contributes to both viral and host cell survival during latent infection. Increased understanding of EBNA1 function during latency is essential for development of therapeutic strategies for the treatment of EBV-associated cancers and related disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA093606-11A1
Application #
8578771
Study Section
Virology - A Study Section (VIRA)
Program Officer
Daschner, Phillip J
Project Start
2001-12-01
Project End
2018-04-30
Budget Start
2013-07-16
Budget End
2014-04-30
Support Year
11
Fiscal Year
2013
Total Cost
$321,273
Indirect Cost
$147,612
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Chen, Horng-Shen; Martin, Kayla A; Lu, Fang et al. (2014) Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site. J Virol 88:1703-13
Tempera, Italo; Lieberman, Paul M (2014) Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol 26:22-9
Lu, Fang; Tempera, Italo; Lee, Hyunna T et al. (2014) EBNA1 binding and epigenetic regulation of gastrokine tumor suppressor genes in gastric carcinoma cells. Virol J 11:12
Tsai, Kevin; Chan, Lilian; Gibeault, Rebecca et al. (2014) Viral reprogramming of the Daxx histone H3.3 chaperone during early Epstein-Barr virus infection. J Virol 88:14350-63
Chen, Horng-Shen; Lu, Fang; Lieberman, Paul M (2013) Epigenetic regulation of EBV and KSHV latency. Curr Opin Virol 3:251-9
Knipe, David M; Lieberman, Paul M; Jung, Jae U et al. (2013) Snapshots: chromatin control of viral infection. Virology 435:141-56
Arvey, Aaron; Tempera, Italo; Lieberman, Paul M (2013) Interpreting the Epstein-Barr Virus (EBV) epigenome using high-throughput data. Viruses 5:1042-54
Dheekollu, Jayaraju; Wiedmer, Andreas; Hayden, James et al. (2011) Timeless links replication termination to mitotic kinase activation. PLoS One 6:e19596
Dheekollu, Jayaraju; Lieberman, Paul M (2011) The replisome pausing factor Timeless is required for episomal maintenance of latent Epstein-Barr virus. J Virol 85:5853-63
Lu, Fang; Wikramasinghe, Priyankara; Norseen, Julie et al. (2010) Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1). Virol J 7:262

Showing the most recent 10 out of 35 publications